All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your Lupus Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Serological activity in systemic lupus erythematosus (SLE) is characterized by the presence of anti-double-stranded DNA antibodies and/or hypocomplementemia. Some patients with SLE exhibit persistent serological activity, despite clinical quiescence. Appropriate use of glucocorticoid (GC) therapy and withdrawal in these serologically active, clinically quiescent (SACQ) patients needs to be investigated.
Katsumata et al. recently published an article in Annals of the Rheumatic Diseases assessing the risk of flare and damage accrual after tapering GCs in patients with modified SACQ (mSACQ; SACQ not-considering duration) with SLE.1 Here, we summarize their key findings.
Figure 1. Risk of A overall flare, B severe flare, and C damage accrual when tapering GCs in mSACQ patients with SLE*
CI, confidence interval; GC, glucocorticoid; HR, hazard ratio; mSACQ, modified serologically active clinically quiescent; SLE, systemic lupus erythematosus.
*Data from Katsumata, et al.1
Key learnings |
|
Subscribe to get the best content related to lupus delivered to your inbox